Dr. Vijaendreh Subramanian

DR. VIJAENDREH SUBRAMANIAM
MBBS (University Malaya), MRCOG (UK),
Board Certified Consultant Obstetrician and Gynae-oncologist
Specialist in Laparoscopic (keyhole) Surgery
Member of the International Organization of Integrative Cancer Physicians
(IOICP), USA
Dr. Vijaendreh Subramaniam (Dr. Vijae) is currently ,a Senior Consultant
Gynae-Oncologist at Putra Specialist Hospital, Melaka , Malaysia. He
graduated from the University of Malaya and commenced postgraduate
training in Obstetrics and Gynaecology (O&G) in 1991, working at
Raigmore Hospital (NHS) in Scotland. He gained a postgraduate
qualification in O&G from the Royal College Obstetricians and
Gynaecologists (RCOG, UK) in 1994.
In 2003 he furthered his sub-speciality training in Gynae-Oncology in the UK at the St. Bartholomew
Hospital (St. Barts), one of the leading cancer centres in London.
Dr. Vijae is an accomplished surgeon trained in Minimally Invasive Surgery (MIS) in gynaecological
cancers from the world-famous Kurashiki Medical Centre in Japan.
Dr. Vijae has worked in oncology since 1995. Since 2011 he has expanded his practice areas to
include alternative and complementary modalities in an integrative fashion in cancer treatment. He
has travelled extensively throughout the world, learning and observing firsthand from leading
practitioners of integrative medicine. He believes that the best results in cancer treatments are only
possible by integrating the best of conventional therapy and complementary/ alternative therapies.
He is the Director of the Healing Zone which is a one-stop center for a holistic and integrated
management of Cancer
ABSTRACT: Taking Cancer Out Of The Box – BRINGING INTEGRATIVE ONCOLOGY TO THE
MAINSTREAM PRACTICE – CHALLENGES AND OPPORTUNITIES
This presentation will focus on the experiences gained in using an integrative treatment approach in
advanced and recurrent cancers.
While current mainstream conventional treatment approaches are only making minor incremental
improvements to the survival outcome, it has been our continuing experience that it is possible to
achieve higher survival rates, lower complications, lower cost, markedly lower use of chemotherapy,
analgesic, and the increased scope for function sparing surgery.